Investor Update

Reminder: New Format and E-Mail Address for Roche Investor Updates

This is to inform you that, as of 20 July 2020, Roche will send its Investor Updates from a new e-mail account with a new format as a joint-release with our Media Relations department.


Please make sure the following e-mail addresses are added to your ‘safe sender’ list:
roche.investor-relations@roche.com and global.news@roche.com.

Do not hesitate to contact us if you have any questions.

With best regards,

Roche Investor Relations  
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com

Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com

Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
   
Investor Relations North America  
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

 

Attachment